CRNX — Crinetics Pharmaceuticals, Inc.

Crinetics Pharmaceuticals (CRNX) Q1 2026 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $10.7 million, comprising $10.3 million from Palsonify and $0.4 million from a licensing agreement.
• Cost of Product Revenue: $0.2 million; prior costs were expensed as zero-cost inventory.
• R&D Expenses: Increased to $100.1 million from $85.1 million in Q4 2025, driven by ongoing Phase III trials.
• SG&A Expenses: Steady at $50.8 million, down from $53.7 million in Q4 2025.
• Cash Position: $1.3 billion, sufficient to fund operations into 2030.
• Share Count: Approximately 105.4 million shares outstanding (123.5 million fully diluted).

2. Strategic Updates and Business Highlights

• Palsonify Launch: Achieved 232 new patient enrollments in Q1 2026, with strong demand and positive feedback from healthcare providers (HCPs) and patients.
• Market Expansion: Palsonify is gaining traction as a new standard of care for acromegaly, with significant progress in reimbursement coverage (70% of patients reimbursed).
• Pipeline Development: Four major clinical trials are ongoing, with promising data expected from studies on atumelnant and 9682.
• International Expansion: Received European Commission approval for Palsonify and submitted applications in Japan and Brazil, with a disciplined market-by-market approach planned.

3. Forward Guidance and Outlook

• 2026 Operating Expenses: Expected GAAP operating expenses between $600 million and $650 million; non-GAAP operating expenses projected at $480 million to $520 million.
• Palsonify Growth: Confidence in continued growth trajectory, aiming for Palsonify to become the most prescribed treatment for acromegaly.
• International Revenue: No expected revenue from international markets in 2026, but preparations for launches in 2027 are underway.

4. Bad News, Challenges, or Points of Concern

• R&D Spending: Significant increase in R&D expenses may raise concerns about cash burn, although the company has a strong cash position.
• Patient Enrollment Dynamics: While there is momentum, the conversion from enrollment forms to actual patients starting treatment is still a focus.
• Market Competition: The need to establish Palsonify as a preferred treatment amidst existing therapies and the inertia in switching patients remains a challenge.

5. Notable Q&A Insights

• Patient Enrollment: The 15% of treatment-naive patients in Q1 reflects a growing physician confidence in Palsonify.
• Reimbursement Dynamics: The conversion rate from quicker start programs to reimbursed patients is progressing well, with expectations that all patients will eventually gain coverage.
• Prescriber Engagement: Approximately 1,400 patients are currently under the care of prescribers, with a balanced distribution between academic and community settings.
• Safety Monitoring: Ongoing trials are closely monitored for safety, with no significant concerns reported, reinforcing confidence in the drug's profile.
• International Strategy: The company is cautious about entering new markets, focusing on regulatory and reimbursement clarity before committing resources.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, and notable insights from the Q&A session, providing a comprehensive overview of Crinetics Pharmaceuticals' performance and outlook for Q1 2026.